Press coverage about Laboratory Corporation of America Holdings (NYSE:LH) has been trending somewhat positive recently, according to Accern Sentiment. The research group ranks the sentiment of news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Laboratory Corporation of America Holdings earned a news impact score of 0.13 on Accern’s scale. Accern also gave media coverage about the medical research company an impact score of 47.5463017564089 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

Here are some of the news headlines that may have effected Accern Sentiment Analysis’s rankings:

Shares of Laboratory Corporation of America Holdings (NYSE LH) traded down 0.86% during mid-day trading on Thursday, hitting $156.40. 597,838 shares of the stock were exchanged. The stock has a 50-day moving average price of $155.18 and a 200 day moving average price of $144.10. Laboratory Corporation of America Holdings has a 52-week low of $119.51 and a 52-week high of $164.22. The firm has a market cap of $15.92 billion, a price-to-earnings ratio of 21.90 and a beta of 0.94.

Laboratory Corporation of America Holdings (NYSE:LH) last announced its quarterly earnings data on Wednesday, July 26th. The medical research company reported $2.47 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.40 by $0.07. The firm had revenue of $2.50 billion during the quarter, compared to analyst estimates of $2.47 billion. Laboratory Corporation of America Holdings had a net margin of 7.57% and a return on equity of 16.85%. Laboratory Corporation of America Holdings’s revenue was up 4.9% on a year-over-year basis. During the same period last year, the firm posted $2.36 EPS. On average, equities research analysts expect that Laboratory Corporation of America Holdings will post $9.51 earnings per share for the current year.

A number of research firms have weighed in on LH. Morgan Stanley raised their price objective on shares of Laboratory Corporation of America Holdings from $154.00 to $166.00 and gave the company an “overweight” rating in a research note on Thursday. Barclays PLC raised their price objective on shares of Laboratory Corporation of America Holdings from $182.00 to $183.00 and gave the company an “overweight” rating in a research note on Thursday, July 27th. Zacks Investment Research upgraded shares of Laboratory Corporation of America Holdings from a “sell” rating to a “hold” rating in a research note on Thursday, July 27th. Craig Hallum restated a “buy” rating and set a $179.00 price objective (up from $157.00) on shares of Laboratory Corporation of America Holdings in a research note on Thursday, July 27th. Finally, Credit Suisse Group lowered shares of Laboratory Corporation of America Holdings to a “hold” rating and set a $146.00 price objective for the company. in a research note on Thursday, July 13th. They noted that the move was a valuation call. Seven equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. Laboratory Corporation of America Holdings has a consensus rating of “Buy” and an average target price of $159.00.

ILLEGAL ACTIVITY NOTICE: “Somewhat Positive Media Coverage Somewhat Unlikely to Affect Laboratory Corporation of America Holdings (NYSE:LH) Stock Price” was first published by Watch List News and is the property of of Watch List News. If you are viewing this article on another site, it was illegally stolen and reposted in violation of US & international copyright laws. The legal version of this article can be viewed at https://www.watchlistnews.com/somewhat-positive-media-coverage-somewhat-unlikely-to-affect-laboratory-corporation-of-america-holdings-nyselh-stock-price/1470564.html.

In related news, CFO Glenn A. Eisenberg sold 5,968 shares of the stock in a transaction that occurred on Tuesday, August 1st. The shares were sold at an average price of $159.46, for a total value of $951,657.28. Following the completion of the transaction, the chief financial officer now directly owns 18,122 shares of the company’s stock, valued at approximately $2,889,734.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Lance Berberian sold 3,613 shares of the stock in a transaction that occurred on Monday, May 22nd. The shares were sold at an average price of $139.84, for a total transaction of $505,241.92. Following the completion of the transaction, the senior vice president now directly owns 5,789 shares of the company’s stock, valued at $809,533.76. The disclosure for this sale can be found here. Insiders sold a total of 14,581 shares of company stock valued at $2,256,899 over the last ninety days. 0.90% of the stock is currently owned by insiders.

About Laboratory Corporation of America Holdings

Laboratory Corporation of America Holdings is a life sciences company that is integrated in guiding patient care, providing clinical laboratory and end-to-end drug development services. The Company operates as a healthcare diagnostics company. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD).

Insider Buying and Selling by Quarter for Laboratory Corporation of America Holdings (NYSE:LH)

Receive News & Ratings for Laboratory Corporation of America Holdings Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corporation of America Holdings and related companies with Analyst Ratings Network's FREE daily email newsletter.